Anticancer drug R&D landscape in China

Shen Zhao; Hongyun Zhao; Cheng Lv; Jifang Gong; Jian Zhang; Wenfeng Fang; Jin Li; Xichun Hu; Yi Ba; Binghe Xu; Yanqiao Zhang; Yun Fan; Kunyan Li; Xiaoyuan Chen; Zhimin Yang; Lin Shen; Li Zhang

doi:10.1186/s13045-020-00877-3

Anticancer drug R&D landscape in China

J Hematol Oncol. 2020 May 13;13(1):51. doi: 10.1186/s13045-020-00877-3.

Authors

Shen Zhao¹, Hongyun Zhao², Cheng Lv³, Jifang Gong⁴, Jian Zhang⁵, Wenfeng Fang¹, Jin Li⁶, Xichun Hu⁵, Yi Ba⁷, Binghe Xu⁸, Yanqiao Zhang⁹, Yun Fan¹⁰, Kunyan Li¹¹, Xiaoyuan Chen¹², Zhimin Yang¹², Lin Shen¹³, Li Zhang¹⁴

Affiliations

¹ Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Zhongshan School of Medicine, Sun Yat-Sen University, 651 Dongfeng East Road, Guangzhou, 510060, China.
² Department of Clinical Research, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Zhongshan School of Medicine, Sun Yat-Sen University, Guangzhou, China.
³ Department of Translational Medicine, CSPC Pharmaceutical Group Limited, Shanghai, China.
⁴ Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, 52 Fucheng Road, Haidian, Beijing, 100142, China.
⁵ Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
⁶ Department of Oncology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China.
⁷ Department of Medical Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China.
⁸ Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
⁹ Department of Gastrointestinal Oncology, Harbin Medical University Affiliated Cancer Hospital, Harbin, China.
¹⁰ Department of Medical Oncology, Zhejiang Cancer Hospital, Cancer Hospital of University of Chinese Academy of Sciences, Hangzhou, China.
¹¹ Department of Medical Oncology, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Changsha, China.
¹² National Center for Drug Evaluation, National Medical Products Administration, Beijing, China.
¹³ Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, 52 Fucheng Road, Haidian, Beijing, 100142, China. shenlin@bjmu.edu.cn.
¹⁴ Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Zhongshan School of Medicine, Sun Yat-Sen University, 651 Dongfeng East Road, Guangzhou, 510060, China. zhangli6@mail.sysu.edu.cn.

No abstract available

Publication types

Editorial
Research Support, Non-U.S. Gov't

MeSH terms

Antineoplastic Agents / pharmacology
Antineoplastic Agents / therapeutic use*
Biomedical Research
China / epidemiology
Clinical Trials, Phase I as Topic
Drug Development
Drug Discovery
Humans
Neoplasms / drug therapy*
Neoplasms / epidemiology

Substances

Antineoplastic Agents